National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 2 of 2000)

Overview

The National Health Act 1953, enacted by the Parliament of Australia, addresses various aspects of public health and the regulation of pharmaceutical benefits. The Pharmaceutical Benefits Declaration under subsection 85(2AA) was introduced to manage the inclusion and exclusion of certain drugs and medicinal preparations from the Pharmaceutical Benefits Scheme (PBS). This particular legislative instrument, numbered PB 2 of 2000, was made to cease the applicability of certain drugs under Part VII of the National Health Act 1953, effective from 1 February 2000. The policy objective behind this declaration is to ensure the PBS remains effective and safe by removing certain drugs deemed no longer suitable for inclusion. This decision was made after obtaining advice from the Pharmaceutical Benefits Advisory Committee, as mandated by the Act. The enacting body for this declaration was the Department of Health and Aged Care, with Alan William Stevens acting as the delegate of the Minister for Health and Aged Care.

Scope and Application

The Pharmaceutical Benefits Declaration under subsection 85(2AA) of the National Health Act 1953 applies to specific drugs and medicinal preparations listed in the Schedule of the Declaration. This Act impacts entities and individuals involved in the provision, distribution, and administration of these pharmaceutical products within the Commonwealth of Australia. The legislation effectively removes the listed drugs and preparations from the scope of Part VII of the National Health Act 1953, which pertains to the Pharmaceutical Benefits Scheme (PBS). The Declaration is a formal action taken by a designated officer of the Department of Health and Aged Care, following advice from the Pharmaceutical Benefits Advisory Committee. It is effective from 1 February 2000 and includes medications such as Grepafloxacin Hydrochloride Sesquihydrate, Omeprazole and Metronidazole and Amoxycillin Trihydrate, “RVHB Maxamaid”, and Vidarabine. The geographic reach of this legislation is nationwide, encompassing all states and territories of Australia. The Declaration does not explicitly state any exclusions, exemptions, or thresholds, but it is understood that its application is confined to the drugs and preparations specified in its Schedule. The Act may be extended or restricted through subordinate instruments, which would further define the application and scope of the Declaration.

Key Provisions

The primary operative sections of this legislation are found in the declaration made by Alan William Stevens, Acting Assistant Secretary of the Pharmaceutical Benefits Branch, Department of Health and Aged Care, who, in accordance with subsection 85(2AA) of the National Health Act 1953, specifies that certain drugs and medicinal preparations will cease to be subject to Part VII of the Act (section 2). These drugs include Grepafloxacin Hydrochloride Sesquihydrate, Omeprazole and Metronidazole and Amoxycillin Trihydrate, "RVHB Maxamaid", and Vidarabine, as detailed in the Schedule to this Declaration. This Act imposes obligations on the entities and parties it governs by removing certain pharmaceutical products from the scope of Part VII of the National Health Act 1953. These pharmaceutical products are no longer subject to the regulations and provisions that applied to them prior to this declaration. As a result, these drugs will no longer be covered under the Pharmaceutical Benefits Scheme, meaning they will not be subsidised by the government for prescription and will not be subject to the same regulatory scrutiny. In terms of consequences, while the Act does not explicitly state offences or penalties for breach, it can be inferred that any continued listing or supply of the specified drugs under the Pharmaceutical Benefits Scheme would be non-compliant with this declaration. The National Health Act 1953 provides for various civil and criminal penalties for breaches of its provisions, including fines and imprisonment, although the specific penalties are not detailed in this legislative instrument. The extent of the penalties would depend on the nature and severity of the breach, as well as the specific provisions of the National Health Act 1953 that are contravened.